Clinical Trial Update: Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating CD19-targeted CAR-T therapy for refractory juvenile dermatomyositis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Dermatomyositis

Drugs mentioned

• CD19-targeted CAR-T Therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Juvenile Dermatomyositis | Phase 1 | Status: RECRUITING